GPC Biotech To Cut 38 Percent Of Workforce
Latest action comes after the German drug maker announced a restructuring last year due to a Phase III setback with satraplatin.
Latest action comes after the German drug maker announced a restructuring last year due to a Phase III setback with satraplatin.